NL8902406A - Werkwijze voor het bepalen van de endogene trombinepotentiaal van plasma, en bloed alsmede een bij deze werkwijze te gebruiken kit. - Google Patents

Werkwijze voor het bepalen van de endogene trombinepotentiaal van plasma, en bloed alsmede een bij deze werkwijze te gebruiken kit. Download PDF

Info

Publication number: NL8902406A
Authority: NL; Netherlands
Prior art keywords: thrombin; substrate; plasma; process according; amount
Prior art date: 1989-09-27

Application number

NL8902406A

Other languages

English (en)

Dutch (nl)

Original Assignee

Hendrik Coenraad Hemker Prof D

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-09-27

Filing date

1989-09-27

Publication date

1991-04-16

1989-09-27 Application filed by Hendrik Coenraad Hemker Prof D filed Critical Hendrik Coenraad Hemker Prof D

1989-09-27 Priority to NL8902406A priority Critical patent/NL8902406A/nl

1990-09-21 Priority to AT90202509T priority patent/ATE121792T1/de

1990-09-21 Priority to DE69018910T priority patent/DE69018910T2/de

1990-09-21 Priority to DK90202509.7T priority patent/DK0420332T3/da

1990-09-21 Priority to ES90202509T priority patent/ES2072970T3/es

1990-09-21 Priority to EP90202509A priority patent/EP0420332B1/fr

1990-09-27 Priority to US07/588,924 priority patent/US5192689A/en

1990-09-27 Priority to JP02260273A priority patent/JP3137261B2/ja

1991-04-16 Publication of NL8902406A publication Critical patent/NL8902406A/nl

Links

238000000034 method Methods 0.000 title claims abstract description 87
210000004369 blood Anatomy 0.000 title claims abstract description 28
239000008280 blood Substances 0.000 title claims abstract description 28
108090000190 Thrombin Proteins 0.000 claims abstract description 127
229960004072 thrombin Drugs 0.000 claims abstract description 127
239000000758 substrate Substances 0.000 claims abstract description 50
230000015572 biosynthetic process Effects 0.000 claims abstract description 27
238000006243 chemical reaction Methods 0.000 claims abstract description 25
206010053567 Coagulopathies Diseases 0.000 claims abstract description 19
230000035602 clotting Effects 0.000 claims abstract description 19
230000000694 effects Effects 0.000 claims abstract description 18
238000011282 treatment Methods 0.000 claims abstract description 13
239000012190 activator Substances 0.000 claims abstract description 10
230000002785 anti-thrombosis Effects 0.000 claims abstract description 10
229960004676 antithrombotic agent Drugs 0.000 claims abstract description 10
238000002360 preparation method Methods 0.000 claims abstract description 6
239000000137 peptide hydrolase inhibitor Substances 0.000 claims abstract 3
229940124158 Protease/peptidase inhibitor Drugs 0.000 claims abstract 2
210000002381 plasma Anatomy 0.000 claims description 41
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 28
229960002897 heparin Drugs 0.000 claims description 27
229920000669 heparin Polymers 0.000 claims description 27
230000008569 process Effects 0.000 claims description 23
108010000499 Thromboplastin Proteins 0.000 claims description 22
102000002262 Thromboplastin Human genes 0.000 claims description 22
108090000935 Antithrombin III Proteins 0.000 claims description 21
239000003146 anticoagulant agent Substances 0.000 claims description 18
239000003814 drug Substances 0.000 claims description 17
230000005764 inhibitory process Effects 0.000 claims description 9
239000003868 thrombin inhibitor Substances 0.000 claims description 9
229940122388 Thrombin inhibitor Drugs 0.000 claims description 8
239000011541 reaction mixture Substances 0.000 claims description 8
PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 claims description 7
230000003213 activating effect Effects 0.000 claims description 7
239000003795 chemical substances by application Substances 0.000 claims description 7
230000003024 amidolytic effect Effects 0.000 claims description 6
229920000045 Dermatan sulfate Polymers 0.000 claims description 5
101000712605 Theromyzon tessulatum Theromin Proteins 0.000 claims description 5
229940051593 dermatan sulfate Drugs 0.000 claims description 5
AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 claims description 5
150000002500 ions Chemical class 0.000 claims description 5
102000007625 Hirudins Human genes 0.000 claims description 4
108010007267 Hirudins Proteins 0.000 claims description 4
108010038807 Oligopeptides Proteins 0.000 claims description 4
102000015636 Oligopeptides Human genes 0.000 claims description 4
239000003153 chemical reaction reagent Substances 0.000 claims description 4
WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims description 4
229940006607 hirudin Drugs 0.000 claims description 4
210000004623 platelet-rich plasma Anatomy 0.000 claims description 4
239000000376 reactant Substances 0.000 claims description 4
239000000126 substance Substances 0.000 claims description 4
-1 2-naphthylsulfonylglycyl Chemical group 0.000 claims description 3
241001465754 Metazoa Species 0.000 claims description 3
238000003556 assay Methods 0.000 claims description 3
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 2
239000004475 Arginine Substances 0.000 claims description 2
102000009123 Fibrin Human genes 0.000 claims description 2
108010073385 Fibrin Proteins 0.000 claims description 2
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 2
108010080798 N(alpha)-(2-naphthylsulfonylglycyl)-4-amidinophenylalanine piperidide Proteins 0.000 claims description 2
FKMJXALNHKIDOD-LBPRGKRZSA-N TAMe Chemical compound NC(=N)NCCC[C@@H](C(=O)OC)NS(=O)(=O)C1=CC=C(C)C=C1 FKMJXALNHKIDOD-LBPRGKRZSA-N 0.000 claims description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
229950003499 fibrin Drugs 0.000 claims description 2
230000000144 pharmacologic effect Effects 0.000 claims description 2
239000003755 preservative agent Substances 0.000 claims description 2
102100022977 Antithrombin-III Human genes 0.000 claims 4
101100450563 Mus musculus Serpind1 gene Proteins 0.000 claims 4
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 2
108020004511 Recombinant DNA Proteins 0.000 claims 1
210000004027 cell Anatomy 0.000 claims 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 1
VEIWYFRREFUNRC-UHFFFAOYSA-N hydron;piperidine;chloride Chemical compound [Cl-].C1CC[NH2+]CC1 VEIWYFRREFUNRC-UHFFFAOYSA-N 0.000 claims 1
239000002574 poison Substances 0.000 claims 1
231100000614 poison Toxicity 0.000 claims 1
238000006116 polymerization reaction Methods 0.000 claims 1
230000007246 mechanism Effects 0.000 abstract description 3
239000012084 conversion product Substances 0.000 abstract 2
102000004411 Antithrombin III Human genes 0.000 description 17
229960005348 antithrombin iii Drugs 0.000 description 17
108010094028 Prothrombin Proteins 0.000 description 13
102100027378 Prothrombin Human genes 0.000 description 12
208000007536 Thrombosis Diseases 0.000 description 12
229940039716 prothrombin Drugs 0.000 description 12
238000012360 testing method Methods 0.000 description 12
102000004032 Heparin Cofactor II Human genes 0.000 description 11
108090000481 Heparin Cofactor II Proteins 0.000 description 11
230000002779 inactivation Effects 0.000 description 10
229940079593 drug Drugs 0.000 description 9
238000002474 experimental method Methods 0.000 description 6
229940127215 low-molecular weight heparin Drugs 0.000 description 6
239000000047 product Substances 0.000 description 6
TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 5
108010074860 Factor Xa Proteins 0.000 description 5
230000004913 activation Effects 0.000 description 5
230000007423 decrease Effects 0.000 description 5
239000003112 inhibitor Substances 0.000 description 5
238000005259 measurement Methods 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
230000008034 disappearance Effects 0.000 description 4
239000000203 mixture Substances 0.000 description 4
230000003287 optical effect Effects 0.000 description 4
150000003904 phospholipids Chemical group 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
229940127219 anticoagulant drug Drugs 0.000 description 3
230000010100 anticoagulation Effects 0.000 description 3
PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 3
230000015271 coagulation Effects 0.000 description 3
238000005345 coagulation Methods 0.000 description 3
230000023597 hemostasis Effects 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
230000009467 reduction Effects 0.000 description 3
239000003998 snake venom Substances 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
102100033312 Alpha-2-macroglobulin Human genes 0.000 description 2
108010027612 Batroxobin Proteins 0.000 description 2
102000015081 Blood Coagulation Factors Human genes 0.000 description 2
108010039209 Blood Coagulation Factors Proteins 0.000 description 2
102000004506 Blood Proteins Human genes 0.000 description 2
108010017384 Blood Proteins Proteins 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108010014173 Factor X Proteins 0.000 description 2
229920002971 Heparan sulfate Polymers 0.000 description 2
101001038021 Lonomia obliqua Lopap Proteins 0.000 description 2
108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 2
230000009471 action Effects 0.000 description 2
230000001858 anti-Xa Effects 0.000 description 2
239000003114 blood coagulation factor Substances 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
235000011148 calcium chloride Nutrition 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
230000002301 combined effect Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
230000006623 intrinsic pathway Effects 0.000 description 2
239000003055 low molecular weight heparin Substances 0.000 description 2
230000037361 pathway Effects 0.000 description 2
230000002085 persistent effect Effects 0.000 description 2
230000035484 reaction time Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
230000001732 thrombotic effect Effects 0.000 description 2
239000002435 venom Substances 0.000 description 2
210000001048 venom Anatomy 0.000 description 2
231100000611 venom Toxicity 0.000 description 2
KWFSIAWLJHTUDY-QRPNPIFTSA-N (2S)-2-amino-3-phenylpropanoic acid piperidine Chemical compound C1CCNCC1.OC(=O)[C@@H](N)CC1=CC=CC=C1 KWFSIAWLJHTUDY-QRPNPIFTSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
241000965254 Apostichopus japonicus Species 0.000 description 1
108010065152 Coagulase Proteins 0.000 description 1
102100022641 Coagulation factor IX Human genes 0.000 description 1
102100023804 Coagulation factor VII Human genes 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
229940123900 Direct thrombin inhibitor Drugs 0.000 description 1
108010076282 Factor IX Proteins 0.000 description 1
108010048049 Factor IXa Proteins 0.000 description 1
108010023321 Factor VII Proteins 0.000 description 1
108010054218 Factor VIII Proteins 0.000 description 1
102000001690 Factor VIII Human genes 0.000 description 1
108010074105 Factor Va Proteins 0.000 description 1
229920002683 Glycosaminoglycan Polymers 0.000 description 1
208000031220 Hemophilia Diseases 0.000 description 1
208000009292 Hemophilia A Diseases 0.000 description 1
229920000209 Hexadimethrine bromide Polymers 0.000 description 1
108010018398 N(alpha)-phosphorylalanylproline Proteins 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
241000272112 Oxyuranus scutellatus Species 0.000 description 1
229930003448 Vitamin K Natural products 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000001455 anti-clotting effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003593 chromogenic compound Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000007819 clotting time assay Methods 0.000 description 1
AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
238000010668 complexation reaction Methods 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
239000002360 explosive Substances 0.000 description 1
229960004222 factor ix Drugs 0.000 description 1
229940012413 factor vii Drugs 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
229940099563 lactobionic acid Drugs 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000007774 longterm Effects 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
229940019331 other antithrombotic agent in atc Drugs 0.000 description 1
230000007170 pathology Effects 0.000 description 1
229940043138 pentosan polysulfate Drugs 0.000 description 1
SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000009291 secondary effect Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
239000004575 stone Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
108010056765 thrombin alpha 2-macroglobulin complex Proteins 0.000 description 1
230000002345 thrombinlike Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000004448 titration Methods 0.000 description 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
229940038773 trisodium citrate Drugs 0.000 description 1
238000002371 ultraviolet--visible spectrum Methods 0.000 description 1
235000019168 vitamin K Nutrition 0.000 description 1
239000011712 vitamin K Substances 0.000 description 1
150000003721 vitamin K derivatives Chemical class 0.000 description 1
229940046010 vitamin k Drugs 0.000 description 1
229940019333 vitamin k antagonists Drugs 0.000 description 1
238000004804 winding Methods 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2337/00—N-linked chromogens for determinations of peptidases and proteinases
- C12Q2337/10—Anilides
- C12Q2337/12—Para-Nitroanilides p-NA
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
- G01N2333/75—Fibrin; Fibrinogen
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
- G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
- G01N2333/8121—Serpins
- G01N2333/8128—Antithrombin III
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/974—Thrombin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Physics & Mathematics (AREA)
Wood Science & Technology (AREA)
Urology & Nephrology (AREA)
Zoology (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pathology (AREA)
Neurosurgery (AREA)
Biophysics (AREA)
General Physics & Mathematics (AREA)
Medicinal Chemistry (AREA)
Food Science & Technology (AREA)
Cell Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)

NL8902406A 1989-09-27 1989-09-27 Werkwijze voor het bepalen van de endogene trombinepotentiaal van plasma, en bloed alsmede een bij deze werkwijze te gebruiken kit. NL8902406A (nl)

Priority Applications (8)

Application Number	Priority Date	Filing Date	Title
NL8902406A NL8902406A (nl)	1989-09-27	1989-09-27	Werkwijze voor het bepalen van de endogene trombinepotentiaal van plasma, en bloed alsmede een bij deze werkwijze te gebruiken kit.
AT90202509T ATE121792T1 (de)	1989-09-27	1990-09-21	Verfahren zur bestimmung des endogenen thrombinpotentials von plasma und blut und reagenziensatz zur verwendung in besagtem verfahren.
DE69018910T DE69018910T2 (de)	1989-09-27	1990-09-21	Verfahren zur Bestimmung des endogenen Thrombinpotentials von Plasma und Blut und Reagenziensatz zur Verwendung in besagtem Verfahren.
DK90202509.7T DK0420332T3 (da)	1989-09-27	1990-09-21	Fremgangsmåde til bestemmelse af det endogene trombinpotentiale af plasma og blod, samt et kit til anvendelse ved fremgangsmåden
ES90202509T ES2072970T3 (es)	1989-09-27	1990-09-21	Metodo para determinar el potencial de trombina endogeno del plasma y de la sangre, y tambien un equipo para su uso en dicho metodo.
EP90202509A EP0420332B1 (fr)	1989-09-27	1990-09-21	Procédé de détermination du potentiel de thrombine endogène dans le plasma ou le sang, et jeu de réchange pour son utilisation dans cette méthode
US07/588,924 US5192689A (en)	1989-09-27	1990-09-27	Method for determining the endogenous thrombin potential of plasma and blood
JP02260273A JP3137261B2 (ja)	1989-09-27	1990-09-27	血しょうおよび血液の内因性トロンビンポテンシャルの測定方法と同方法に使用するキット

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
NL8902406		1989-09-27
NL8902406A NL8902406A (nl)	1989-09-27	1989-09-27	Werkwijze voor het bepalen van de endogene trombinepotentiaal van plasma, en bloed alsmede een bij deze werkwijze te gebruiken kit.

Publications (1)

Publication Number	Publication Date
NL8902406A true NL8902406A (nl)	1991-04-16

Family

ID=19855364

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL8902406A NL8902406A (nl)	1989-09-27	1989-09-27	Werkwijze voor het bepalen van de endogene trombinepotentiaal van plasma, en bloed alsmede een bij deze werkwijze te gebruiken kit.

Country Status (8)

Country	Link
US (1)	US5192689A (fr)
EP (1)	EP0420332B1 (fr)
JP (1)	JP3137261B2 (fr)
AT (1)	ATE121792T1 (fr)
DE (1)	DE69018910T2 (fr)
DK (1)	DK0420332T3 (fr)
ES (1)	ES2072970T3 (fr)
NL (1)	NL8902406A (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1992007954A1 (fr) *	1990-11-05	1992-05-14	Baxter Diagnostics Inc.	Procede de determination de la concentration d'anticoagulants
DE4203980A1 (de) *	1992-02-11	1993-08-12	Max Planck Gesellschaft	Verfahren zur bestimmung von hirudin und synthetischen thrombininhibitoren
AT397391B (de) *	1992-05-15	1994-03-25	Immuno Ag	Verwendung von prothrombinfragmenten
EP0585504A1 (fr) *	1992-09-04	1994-03-09	Pentapharm A.G.	Activateur de prothrombine dépendant de phospholipides et son application dans les tests pour lupus anticoagulants
DE69615339T2 (de) *	1995-01-10	2002-07-04	Hemker, Hendrik Coenraad	Verfahren zum nachweis des endogenen thrombin-potentials und thrombin substrate zur verwendung in diesen verfahren
DE19533817C2 (de) *	1995-09-13	1999-12-09	Max Planck Gesellschaft	Komplex-gebundene Hemmstoffe aktivierbarer Stoffwechselenzyme als molekulare Marker zur Diagnostik und Therapieüberwachung
SE9600216D0 (sv) *	1996-01-18	1996-01-18	Hans Arne Hansson	Styrning av läkningsprocesser
DE19904674A1 (de) *	1999-02-04	2000-08-31	Haemosys Gmbh	Verfahren zur Bestimmung der Konzentration von Thrombininhibitoren
US6740496B1 (en)	1999-03-04	2004-05-25	Synapse B.V.	Determination of biologically active forms of proteolytic enzymes
AUPP971299A0 (en)	1999-04-12	1999-05-06	South Eastern Sydney Area Health Service	Procoagulant assay
US6645768B1 (en)	2000-10-27	2003-11-11	Biomerieux, Inc.	Reagent and kit for determining global coagulability and hemostatic potential
US6743596B1 (en)	2000-10-27	2004-06-01	Biomerieux, Inc.	Method of determining global coagulability hemostatic potential
EP1367135A1 (fr)	2002-05-29	2003-12-03	Pentapharm AG	Procédé amélioré pour l'évaluation de formation de thrombin dans plasma sanguine
DE10360628A1 (de) *	2003-12-19	2005-07-21	Dade Behring Marburg Gmbh	Kontrollplasma für Thrombinaktivitätstests
GB0402719D0 (en) *	2004-02-07	2004-03-10	Royal College Of Surgeons Ie	A method of detecting incomplete inhibition of enzymes in individuals undergoing enzyme inhibitor therapy
EP1745145A4 (fr) *	2004-05-11	2008-03-26	Heptest Lab Inc	Compositions, kit et procede en une etape permettant de surveiller des composes possedant des activites d'antifacteur xa et/ou d'antifacteur iia
US7148067B2 (en) *	2004-08-31	2006-12-12	The Board Of Trustees Of The University Of Illinois	Thromboplastin reagents
DE102004059055A1 (de)	2004-12-07	2006-06-08	Dade Behring Marburg Gmbh	Verfahren zur automatischen Bestimmung des endogenen Thrombinpotenzials
ES2357112T3 (es)	2005-01-07	2011-04-18	Stichting Katholieke Universiteit	Ensayo de hemostasia.
DE102005003145B4 (de)	2005-01-21	2006-10-19	Dade Behring Marburg Gmbh	Stablies, chromogenes Flüssigreagenz und dessen Verwendung in gerinnungsdiagnostischen Tests
US20080260858A1 (en) *	2005-02-16	2008-10-23	The Board Of Trustees Of The University Of Illnois	Universal Procoagulant
DE102005008066A1 (de)	2005-02-22	2006-08-24	Haemosys Gmbh	Verfahren zur Bestimmung der Gesamtgerinnungsaktivität einer Blut- oder Plasmaprobe
JP2008531692A (ja) *	2005-03-04	2008-08-14	ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ	凝固及び線維素溶解カスケードのモジュレーター
WO2007073597A1 (fr)	2005-12-27	2007-07-05	Mcmaster University	Essai pour effectuer des mesures sur des enzymes au moyen d'un substrat modifie comprenant un substrat fixe a une macromolecule via un espaceur
US9091700B2 (en)	2005-12-27	2015-07-28	Mcmaster University	Modified peptide substrate
DE102006035899A1 (de)	2006-07-31	2008-02-07	Dade Behring Marburg Gmbh	Polysacharid-Peptid-Konjugate zur Verwendung als Thrombinsubstrate
CN101221188B (zh) *	2007-01-12	2012-04-18	上海太阳生物技术有限公司	临床检验凝血酶时间(tt)测定体外诊断试剂盒
DE102007017906A1 (de)	2007-04-17	2008-10-23	Dade Behring Marburg Gmbh	Verfahren zur Bestimmung der Reaktions-Lag-Phase in einer analytabhängigen Reaktion
RU2377246C2 (ru) *	2007-06-08	2009-12-27	Государственное учреждение гематологический научный центр Российской академии медицинских наук (ГУ ГНЦ РАМН)	Синтетическое производное пептида, проявляющее антикоагулянтную активность
WO2009046194A2 (fr) *	2007-10-05	2009-04-09	The Board Of Trustees Of The University Of Illinois	Produit d'étanchéité de fibrine
WO2009061697A1 (fr)	2007-11-09	2009-05-14	The Board Of Trustees Of The University Of Illinois	Antagoniste d'anticoagulant et procoagulant anti-hémophilique
DE102007062323A1 (de)	2007-12-21	2009-06-25	Siemens Healthcare Diagnostics Products Gmbh	Langzeitstabiles Thromboplastin-Reagenz
US20090298103A1 (en) *	2008-05-20	2009-12-03	The University Of Vermont And State Agriculture College	Predicting hemostatic risk; dependence on plasma composition
US8293493B2 (en) *	2010-01-27	2012-10-23	Adventist Health System/Sunbelt, Inc.	Thrombin generation determination method
EP2395354A1 (fr)	2010-06-10	2011-12-14	Siemens Healthcare Diagnostics Products GmbH	Test d'activité homogène destiné à la détermination de réactions enzymatiques
MX351846B (es) *	2010-09-20	2017-10-31	Q Sera Pty Ltd	Preparacion de suero.
DK3228714T3 (da)	2010-12-14	2019-06-17	Stichting Katholieke Univ	Kemiluminescens-baseret hæmostase-assay
US9561300B2 (en)	2011-09-26	2017-02-07	Yes, Inc.	Hemostatic compositions and dressings for bleeding
WO2013056116A1 (fr) *	2011-10-12	2013-04-18	The Trustees Of Columbia University In The City Of New York	Pansement hémostatique pour saignement artériel
EP2677037B1 (fr)	2012-06-21	2016-04-13	Synapse B.V.	Mesure simultanée de la génération de thrombine et résistance des caillots dans du plasma et du sang entier
WO2014098056A1 (fr) *	2012-12-18	2014-06-26	第一三共株式会社	Procédé de mesure de la production de thrombine
WO2015013495A1 (fr) *	2013-07-26	2015-01-29	The University Of North Carolina At Chapel Hill	Procédés et compositions permettant la détection d'inhibiteurs de coagulation
EP3388838B1 (fr)	2016-01-29	2022-02-16	Sony Group Corporation	Analyse de coagulation sanguine
ES2911600T3 (es)	2017-06-20	2022-05-20	Inst Nat Sante Rech Med	Métodos para identificar si pacientes con insuficiencia cardiaca aguda descompensada (ICAD) presentan un estado hipercoagulable
EP3489692A1 (fr)	2017-11-28	2019-05-29	Siemens Healthcare Diagnostics Products GmbH	Réactif pour le temps de prothrombine contenant un chélateur du fer
US12522855B2 (en)	2019-07-31	2026-01-13	Tel Hashomer Medical Research Infrastructure And Services Ltd.	Methods and kits for identifying thrombus origin and optimizing post-ischemic event treatment
WO2022133109A1 (fr) *	2020-12-16	2022-06-23	Arizona Board Of Regents On Behalf Of The University Of Arizona	Compositions et méthodes destinées à traiter et prévenir un empoisonnement par du venin
EP4239338A1 (fr)	2022-03-03	2023-09-06	Siemens Healthcare Diagnostics Products GmbH	Essai général destiné à la détermination de l'état du système de coagulation sanguine
CN117143179B (zh) *	2023-09-18	2024-07-12	安徽峆一药业股份有限公司	一种凝血酶发色底物s-2238的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4169015A (en) *	1975-07-11	1979-09-25	Ab Kabi	Novel chromogenic thrombin substrates
US4247454A (en) *	1975-07-11	1981-01-27	Ab Kabi	Novel chromogenic thrombin substrates
US4061625A (en) *	1975-07-11	1977-12-06	Ab Kabi	Novel chromogenic thrombin substrates
US4289498A (en) *	1979-01-08	1981-09-15	Ortho Diagnostics, Inc.	One-stage prothrombin assay and compositions useful therein
WO1982001377A1 (fr) *	1980-10-09	1982-04-29	Lill Helmut	Procede de determination d'une bm ('binding moderately') antithrombine
DE3244030A1 (de) *	1982-11-27	1984-05-30	Behringwerke Ag, 3550 Marburg	Chromogene verbindungen, verfahren zu ihrer herstellung und ihre verwendung
US4594326A (en) *	1983-05-09	1986-06-10	Wade Stephen E	Time-integrated measurement for determining substances in biological fluids
DE3407280A1 (de) *	1984-02-28	1985-09-19	Gödecke AG, 1000 Berlin	Testsatz zur bestimmung der aktivierten partiellen thromboplastinzeit (ptt) mit erhoehter heparinempfindlichkeit
US4851336A (en) *	1985-09-05	1989-07-25	Yin E Thye	Composition, kit, and method for assaying heparinano a method for making the composition

1989
- 1989-09-27 NL NL8902406A patent/NL8902406A/nl not_active Application Discontinuation
1990
- 1990-09-21 AT AT90202509T patent/ATE121792T1/de not_active IP Right Cessation
- 1990-09-21 DE DE69018910T patent/DE69018910T2/de not_active Expired - Lifetime
- 1990-09-21 EP EP90202509A patent/EP0420332B1/fr not_active Expired - Lifetime
- 1990-09-21 DK DK90202509.7T patent/DK0420332T3/da active
- 1990-09-21 ES ES90202509T patent/ES2072970T3/es not_active Expired - Lifetime
- 1990-09-27 US US07/588,924 patent/US5192689A/en not_active Expired - Lifetime
- 1990-09-27 JP JP02260273A patent/JP3137261B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP0420332B1 (fr)	1995-04-26
DE69018910D1 (de)	1995-06-01
ES2072970T3 (es)	1995-08-01
DE69018910T2 (de)	1995-08-24
EP0420332A2 (fr)	1991-04-03
EP0420332A3 (en)	1991-05-08
DK0420332T3 (da)	1995-07-03
ATE121792T1 (de)	1995-05-15
JPH03236798A (ja)	1991-10-22
US5192689A (en)	1993-03-09
JP3137261B2 (ja)	2001-02-19

Legal Events

Date	Code	Title	Description
1992-05-06	BV	The patent application has lapsed

Publication	Publication Date	Title
NL8902406A (nl)	1991-04-16	Werkwijze voor het bepalen van de endogene trombinepotentiaal van plasma, en bloed alsmede een bij deze werkwijze te gebruiken kit.
Bauer et al.	1987	The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation
Hemker et al.	1995	Thrombin generation in plasma: its assessment via the endogenous thrombin potential
Samama et al.	2010	Assessment of laboratory assays to measure rivaroxaban–an oral, direct factor Xa inhibitor
Kitchen	2000	Problems in laboratory monitoring of heparin dosage.
AU776845B2 (en)	2004-09-23	Hematological assay and reagent
US5051357A (en)	1991-09-24	Method and assay using inactivation of factors Va and VIIIa by activated Protein C to diagnose thrombic disease or assay for Protein C and kit therefor
EP0509086B1 (fr)	1995-04-12	Procede de determination de la concentration d'anticoagulants
EP2529221B1 (fr)	2017-12-20	Procédé de détermination de la génération de thrombine
Colucci et al.	2008	Mild hyperhomocysteinemia is associated with increased TAFI levels and reduced plasma fibrinolytic potential
CA1060324A (fr)	1979-08-14	Methode de dosage du facteur xal dans le sang
Wessler et al.	1974	On the antithrombotic action of heparin
Parsi et al.	2009	In vitro effects of detergent sclerosants on antithrombotic mechanisms
Scott et al.	1989	Factors influencing the acceleration of human factor XIa inactivation by antithrombin III
Pyrogova et al.	2016	Level of overall hemostasis potential in donor and patient plasma in pathology
MXPA04005518A (es)	2005-04-19	Prueba de heparina de bajo peso molecular, sistema y reactivo para el mismo.
CA2039173C (fr)	1997-04-01	Dosage chromogene du facteur ix
Triplett	1979	Heparin: biochemistry, therapy, and laboratory monitoring
Nieuwenhuys et al.	2000	Monitoring hypocoagulant conditions in rat plasma: factors determining the endogenous thrombin potential of tissue factor-activated plasma
Fernández et al.	1997	Activated protein C correlates inversely with thrombin levels in resting healthy individuals
Kaiser et al.	1997	In vitro studies on the effect of activated protein C on platelet activation and thrombin generation
Vinazzer	1977	Photometric assay of platelet factor 4 with a chromogenic substrate
Brack et al.	1993	Prothrombin fragment F1+ 2 concentrations for monitoring anticoagulation therapy with heparin
Scully	1983	The use of an automated analyzer in the evaluation of antithrombin III and heparin
Peyrou et al.	1997	The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma–the need for using absolute anti-factor Xa and antithrombin activities